Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

377 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prostate-specific antigen response and clinical progression-free survival in Black and White men with chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide in a real-world setting.
Freedland SJ, Hong A, El-Chaar N, Murty S, Ramaswamy K, Coutinho AD, Nimke D, Morgans AK. Freedland SJ, et al. Among authors: ramaswamy k. Prostate Cancer Prostatic Dis. 2023 Sep;26(3):523-530. doi: 10.1038/s41391-022-00622-6. Epub 2022 Dec 14. Prostate Cancer Prostatic Dis. 2023. PMID: 36517634 Free PMC article.
Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate.
Tagawa ST, Ramaswamy K, Huang A, Mardekian J, Schultz NM, Wang L, Sandin R, Lechpammer S, George DJ. Tagawa ST, et al. Among authors: ramaswamy k. Prostate Cancer Prostatic Dis. 2021 Dec;24(4):1032-1040. doi: 10.1038/s41391-021-00318-3. Epub 2021 Feb 21. Prostate Cancer Prostatic Dis. 2021. PMID: 33612825 Free PMC article.
Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trials.
Tombal BF, Freedland SJ, Armstrong AJ, Beer TM, Stenzl A, Sternberg CN, Hussain M, Ganguli A, Ramaswamy K, Bhadauria H, Ivanescu C, Turnbull J, Holmstrom S, Saad F. Tombal BF, et al. Among authors: ramaswamy k. Prostate Cancer Prostatic Dis. 2022 Feb;25(2):288-295. doi: 10.1038/s41391-021-00447-9. Epub 2021 Sep 13. Prostate Cancer Prostatic Dis. 2022. PMID: 34518652 Free PMC article.
Correction to: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate.
Tagawa ST, Ramaswamy K, Huang A, Mardekian J, Schultz NM, Wang L, Sandin R, Lechpammer S, George DJ. Tagawa ST, et al. Among authors: ramaswamy k. Prostate Cancer Prostatic Dis. 2022 Apr;25(4):800-801. doi: 10.1038/s41391-021-00401-9. Prostate Cancer Prostatic Dis. 2022. PMID: 35039606 Free PMC article. No abstract available.
The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups.
Stenzl A, Szmulewitz RZ, Petrylak D, Holzbeierlein J, Villers A, Azad A, Alcaraz A, Alekseev B, Iguchi T, Shore ND, Gomez-Veiga F, Ivanescu C, Rosbrook B, Ramaswamy K, Ganguli A, Haas GP, Armstrong AJ. Stenzl A, et al. Among authors: ramaswamy k. Prostate. 2022 Sep;82(13):1237-1247. doi: 10.1002/pros.24396. Epub 2022 Jun 8. Prostate. 2022. PMID: 35675470 Clinical Trial.
Correction: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate.
Tagawa ST, Ramaswamy K, Huang A, Mardekian J, Schultz NM, Wang L, Sandin R, Lechpammer S, George DJ. Tagawa ST, et al. Among authors: ramaswamy k. Prostate Cancer Prostatic Dis. 2022 Apr;25(4):804. doi: 10.1038/s41391-022-00578-7. Prostate Cancer Prostatic Dis. 2022. PMID: 35840724 Free PMC article. No abstract available.
377 results